Objective: Previous studies suggest that the brain-derived neurotrophic factor (BDNF) Val66Met (rs6265) polymorphism may influence symptom onset in Alzheimer's disease (AD). Our recent cross-sectional findings suggest that Met66 may influence clinical expression in dominantly inherited AD (DIAD) through its effects on tau. However, it remains unclear whether carriage of Met66 in DIAD results in faster increases in cerebrospinal fluid (CSF) tau and ptau 181 , and whether these increases are associated with accelerated brain volume loss and memory decline. Methods: A total of 211 subjects (101 mutation noncarriers, 110 mutation carriers), who were cognitively normal, as defined by a Clinical Dementia Rating global score of 0, completed assessments of cognitive function, neuroimaging, and CSF sampling over 3.5 years as part of the Dominantly Inherited Alzheimer's Network. Results: In mutation carriers, Met66 carriers showed faster memory decline (4×), hippocampal volume loss (16×), and CSF tau and ptau 181 increases (6×) than Val66 homozygotes. BDNF did not influence rates of cortical β-amyloid accumulation or change in CSF Aβ 42 levels in mutation carriers. In mutation noncarriers, BDNF genotype had no effect on change in cognition, brain volume, cortical β-amyloid accumulation, or change in any CSF measures of tau, ptau 181 , and CSF Aβ 42 . Interpretation: As in sporadic AD, the deleterious effects of β-amyloid on cognitive function, brain volume loss, and CSF tau in DIAD mutation carriers are less in Val66 homozygotes. The BDNF Val66Met polymorphism should be considered as a potential moderator of clinical trial outcomes in current treatment and prevention trials in DIAD and sporadic AD.
D ominantly inherited Alzheimer's disease (DIAD) is caused by mutations in the amyloid precursor protein (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2), which lead to a rapid accumulation of beta-amyloid (Aβ), which, in turn, gives rise to increased cerebrospinal fluid (CSF) tau, neurofibrillary tangles, loss of brain volume, cognitive decline, and, ultimately, dementia. 1, 2 The temporal sequence of biomarker changes and their clinical manifestation in DIAD are acknowledged widely as being similar to that in sporadic (AD). [1] [2] [3] [4] Hence, understanding disease progression in DIAD is important for understanding AD pathophysiological process in general. Because DIAD mutations have almost complete penetrance, we have developed predictive models for the timing of symptom onset in DIAD mutation carriers. 1, 5 However, these account for only 50% of the variance in symptom onset in mutation carriers, 5 suggesting that other factors may modify relationships between DIAD mutations and their phenotypic expression. Converging evidence from sporadic AD and DIAD studies suggest that the brain-derived neurotrophic factor (BDNF) Val66Met (rs6265) polymorphism may influence symptom onset. [6] [7] [8] [9] In sporadic AD, Met66 carriers show faster cognitive decline and hippocampal volume loss in both preclinical and prodromal stages. [6] [7] [8] [9] [10] However, the Met66 allele does not increase Aβ accumulation and, in β-amyloid-negative individuals, does not influence cognitive decline or neurodegeneration. 6, 7 This led us to propose that in β-amyloid-positive nondemented older adults, Met66 reduces resilience to β-amyloid associated neurotoxicity, 11, 12 possibly through modifying central nervous system (CNS) BDNF levels as a response to inflammatory processes that occur early in the course of AD. 13 In DIAD, BDNF Val66Met can also influence symptom onset. Cognitively normal young DIAD mutation carriers who were Met66 carriers showed greater cognitive impairment and lower hippocampal glucose metabolism than matched Val66 homozygotes. 10 This was despite both Met66 carriers and Val66 homozygotes having elevated and equivalent levels of cortical Aβ compared to matched controls. 10 These cross-sectional findings also suggested that Met66 influenced clinical expression in DIAD by increasing tau, because DIAD mutation carriers who carried the Met66 allele showed CSF tau and phosphorylated tau (ptau 181 ) levels that were 25% greater than DIAD mutation carriers who were Val66 homozygotes. 10 The hypothesis that BDNF influences tau levels requires challenge in a prospective study given that it is not known whether carriage of Met66 in DIAD is associated with faster increases in CSF tau and ptau 181 , and whether such increases accompany greater brain volume loss and memory decline. Furthermore, to confirm the role of Met66 in AD, it is necessary to show that it does not influence memory decline, brain volume loss, and tau levels in β-amyloid-negative mutation noncarriers.
Subjects and Methods

Subjects
Individuals at risk for carrying a DIAD mutation (ie, PSEN1, PSEN2, or APP mutations) were enrolled in the Dominantly Inherited Alzheimer Network (DIAN) study and followed over an average of 3 years. Subjects from families with known pathogenic DIAD mutations were recruited from 197 families at sites in the United States (6), United Kingdom (1), and Australia (3). 1 Recruitment and enrollment processes have been detailed previously. 1 Subjects were included for analysis in this study if they had more than one cognitive and biomarker assessment. Prospective data from 211 cognitively normal subjects (101 mutation noncarriers, 110 preclinical mutation carriers), defined by a Clinical Dementia Rating (CDR) of 0, 14 and who had completed assessments of cognition, neuroimaging, CSF sampling, and BDNF Val66Met genotyping from January 2009 to June 2017 were included (DataFreeze 12). On average, preclinical mutation carriers were followed over a period of 3.56 (standard deviation [SD], 1.51) years. Similarly, mutation noncarriers were followed over a period of 3.75 (SD, 1.53) years. Table 1 shows the demographic characteristics of the sample. Table 2 shows the demographic characteristics of the subsample who underwent lumbar punctures.
All participants provided written informed consent. All study procedures were approved by the Washington University Human Research Protection Office and the local institutional review boards of each participating site.
Clinical Assessment
Without reference to performance on the neuropsychological tests, a clinician assessed each subject for the presence and severity of clinical symptoms of dementia at baseline (using the CDR scale, for which a CDR total score of 0 indicates cognitive normality).
14 Subjects also completed the Mini-Mental State Examination (MMSE) and the Geriatric Depression Scale (GDS) at baseline.
Neuropsychological Assessment
The DIAN neuropsychological test battery included the Wechsler Memory Scale-Revised Logical Memory (Story A only, immediate and delayed recall); Digit Symbol from the Wechsler Adult Intelligence Scale-Revised; and immediate and delayed recall of a single presentation of a 16-item word list. 15 These tasks, their standardization, and quality control (QC), have been detailed previously and were administered according to standard protocols by trained research assistants. 15 Outcome measures for each neuropsychological test were standardized against the baseline mean and SD of nonmutation carriers. Standardized scores were then averaged to form a composite score for episodic memory (Logical Memory delayed recall, word list learning delayed recall) and for global cognition (Logical Memory delayed recall, word list learning delayed recall, Digit Symbol, and MMSE). 10 Genotyping DNA sequencing to identify pathogenic mutations in APP, PSEN1, and PSEN2 was performed on DNA extracted from peripheral blood samples using methods described previously. 16 Samples were also genotyped with the Infinium HumanExomeCore V1.0 Beadchip (Illumina, Inc., San Diego, CA). Genotyping was performed at The Genome Technology Access Center (GTAC; https://gtac.wustl.edu/) at Washington University. All samples and genotypes underwent stringent QC. Genotype data were cleaned by applying a minimum call rate for singlenucleotide polymorphisms (SNPs) and individuals (98%). SNPs not in Hardy-Weinberg equilibrium (p < 1 × 10 −6 ) were excluded. No SNPs were removed for low minor allele frequency. Sex identification was verified by analysis of Xchromosome SNPs. Unanticipated duplicates were identified using pair-wise genome-wide estimates of proportion identity-bydescent using PLINK v1.9. Genotype data for the BDNF Val66Met (rs6265) polymorphism were extracted using PLINK. Clinicians were blinded to all genetic information, and genetic polymorphisms were not used diagnostically.
Neuroimaging
DIAN neuroimaging protocols have been described previously. 17, 18 Briefly, images from positron emission tomography (PET) using Pittsburgh compound B (PiB; PiB-PET) were coregistered with individual magnetic resonance imaging (MRI) images for region-of-interest determination. For PiB-PET, total neocortical standardized uptake value ratio (SUVR) was used to determine levels of cortical Aβ deposition, using cerebellar gray matter as the reference region and applying partial volume correction using a regional point spread function. 18 
Biochemical Analysis
Fasted CSF was collected in the morning by lumbar puncture. Samples were shipped on dry ice to the DIAN Biomarker Core laboratory. CSF concentrations of Aβ 42 , total tau, and tau phosphorylated at threonine 181 (ptau 181 ) were measured by immunoassay (AlzBio3, Fujirebio [formerly Innogenetics, Ghent, Belgium]). All values met QC standards, including a coefficient of variation of 25% or less, kit "controls" within the expected range as defined by the manufacturer, and measurement consistency between plates of a common sample that was included in each run. All samples were run on a single-assay lot number, with serial samples from a given individual run on the same assay plate. 
Estimated Year to Symptom Onset
Estimated year to expected symptom onset (EYO) was calculated as the age of the participant at the time of the baseline assessment minus the mean age of symptom onset of all other individuals with the same mutation type. 5 Analyses were also repeated using parental EYO, defined as an individual's age minus the age of symptom onset of that individual's parent. 5 
Statistical Analysis
All analyses were conducted in the statistical program R (v3.5.0; R Foundation for Statistical Computing, Vienna, Austria), using the following packages: "ggplot2," "psych," "lme4," and "lmerTest." Data were analyzed separately for preclinical mutation carriers and nonmutation carriers. First, a series of t tests were conducted to determine whether there were differences on any demographic or mood variables between Met66 carriers and Val66 homozygotes at baseline (Table 1) . Any demographic or mood variable that were different between groups were then included as a covariate in subsequent analyses. Although the number of subjects who identified as white or nonwhite were not different between Met66 carriers and Val66 homozygotes (in either preclinical mutation carriers or non-mutation carriers), we included race as a covariate in all analyses because there is a wide variation in population prevalence of the Met66 allele in different races.
In preclinical mutation carriers, we conducted a series of linear mixed models with an unstructured covariance matrix, with each outcome measure (cognition, brain volume, tau, and Aβ) as the dependent variable, and interactions between BDNF group (Met66 carriers vs Val66 homozygotes) × EYO (defined as continuous time-dependent variable) specified as fixed factors. EYO and subjects were included as random factors. Besides race, no other covariates were included in the model because no demographic characteristics differed between groups (Table 1) . Furthermore, because we have shown that APOE ε4 does not influence disease progression in DIAD 5 and does not interact with BDNF to influence cognitive or biomarker outcomes in DIAD, 10 APOE ε4 status was not included as a term in these statistical models. In Aβ-negative nonmutation carriers, we conducted a series of linear mixed models with an unstructured covariance matrix, with each outcome measure (cognition, brain volume, tau, and Aβ) as the dependent variable, and interactions between BDNF group (Met66 carriers versus Val66 homozygotes) × subjects' age (defined as continuous time-dependent variable) specified as fixed factors. EYO and subjects were included as random factors. Because Met66 carriers showed higher levels of depressive symptoms than Val66 homozygotes (Table 1) , depressive symptom scores were included in the model as a covariate. We also included APOE ε4 status as a covariate in these analyses because it presents an increased risk to age-related cognitive decline.
For all analyses, statistical significance for comparisons was set at p < 0.05. Analyses were not adjusted for multiple comparisons because this is a novel area of experimental investigation that provides an important hypothesis to be tested, and the 
Results
Demographic and Clinical Characteristics
In preclinical mutation carriers, EYO did not differ significantly between Val66 homozygotes and Met66 carriers. In nonmutation carriers, age did not differ significantly between Val66 homozygotes and Met66 carriers. Preclinical mutation carriers and mutation noncarriers did not differ on any other demographic characteristic.
Effect of BDNF Val66Met on Rates of Cognitive Decline and Brain Volume Loss in Preclinical Mutation Carriers
In preclinical mutation carriers, decline in episodic memory ( Fig 1A) and global cognition were significantly greater in Met66 carriers compared to Val66 homozygotes (Table 3) , with the magnitude of difference, by convention, large (d > 0.8; Table 4 ). Similarly, when compared to Val66 homozygotes, Met66 carriers also showed significantly faster rates of hippocampal volume loss (Fig 1B) , but not greater reduction in precuneus thickness (Table 3) . These results were unchanged with parental EYO treated as the continuous time-dependent variable. All models have been adjusted for race. CSF = cerebrospinal fluid; EYO = estimated years to symptom onset; PACC = preclinical Alzheimer cognitive composite; PT = precuneus thickness; PiB-PET SUVR = positron emission tomography (using Pittsburgh compound B) standardized uptake value ratio. All estimates have been adjusted for race. CSF = cerebrospinal fluid; MC = mutation carrier; PACC = preclinical Alzheimer cognitive composite; SE = standard error; PiB-PET SUVR = positron emission tomography (using Pittsburgh compound B) standardized uptake value ratio.
Effect of BDNF Val66Met on Rate of Change in Aβ and Tau in Preclinical Mutation Carriers
In preclinical mutation carriers, Met66 carriers and Val66 homozygotes showed equivalent rates of cortical Aβ accumulation and decreases in CSF Aβ 42 (Table 3 ; Fig 1C,D) , with the difference in rates of change for both Aβ biomarkers nonsignificant and small in magnitude (d = 0.1; Table 4 ). However, compared to Val66 homozygotes, Met66 carriers showed significantly greater increases over time in CSF tau and ptau 181 (Table 3 ; Fig 1E,F) , with these differences large in magnitude (ds, 1; Table 4 ). These results were unchanged when parental EYO was used.
Because some have reported sex-specific effects of BDNF Val66Met previously, 19 we repeated our analyses on the main outcome measures (episodic memory, hippocampal volume, CSF tau, and SUVR) accounting for the effects of sex. Our results remained unchanged, and participants' sex was not related to any aspect of memory, neuroimaging or biomarker change, nor did it interact with BDNF to influence change in any of these clinical disease markers (Supplementary Table) . Table 6 . Among Aβ-negative mutation noncarriers, Val66 homozygotes showed no significant deterioration in cognition or hippocampal volume loss compared to Met66 carriers (Table 5 ; Fig 2A,B) , with all group differences small (d = 0.20; Table 6 ). Similarly, in Aβ-negative mutation noncarriers, there were no significant differences between Val66 homozygotes and Met66 carriers on the rate of change in CSF tau, CSF ptau 181 , and Aβ (cortical Aβ and CSF Aβ 42 ; Table 5 ; Fig 2C-F) .
Discussion
The results of this study show that phenotypic expression of DIAD mutations is influenced by the BDNF Val66Met polymorphism, in that carriage of a Met66 allele hastens the onset of AD symptoms through acceleration of Aβ + -related tau accumulation and neurodegeneration. Preclinical mutation carriers who carried the Met66 allele showed faster decline in episodic memory, accompanied by greater loss of hippocampal volume compared to Val66 homozygotes (Fig 1A,B) . This finding is consistent with, and extends, our previous cross-sectional observation that in preclinical DIAD mutation carriers, Met66 carriers show worse memory performance and lower hippocampal glucose metabolic activity than Val66 homozygotes. 10 These results are also in accord with observations in preclinical and prodromal sporadic AD, where Aβ-positive Met66 carriers also showed faster cognitive decline and hippocampal volume loss when compared to Aβ-positive Val66 homozygotes.
6-9 All models have been adjusted for APOE ε4, depressive levels, and race. CSF = cerebrospinal fluid; EYO = estimated years to symptom onset; PACC = preclinical Alzheimer cognitive composite; PiB-PET SUVR = positron emission tomography (using Pittsburgh compound B) standardized uptake value ratio.
Our data also show, for the first time, that in preclinical mutation carriers, Met66 carriers have a faster (ie, 5 and 7 times) rate of increase in CSF tau and ptau 181 than Val66 homozygotes (Fig 1E,F; Table 6 ). This is consistent with, and extends, our previous cross-sectional observation that in preclinical DIAD mutation carriers, CSF tau and ptau 181 levels were 25% higher in Met66 carriers than in Val66 homozygotes. 10 In preclinical mutation carriers who were Val66 homozygotes, levels of CSF tau and ptau 181 were higher than those in nonmutation carriers, but, interestingly, no increase in CSF tau or ptau 181 levels were observed over the mean follow-up period of 3 years (Table 6 ). In contrast, cortical Aβ accumulation, as measured by PiB-PET and decreases in CSF Aβ 42 levels, in preclinical mutation carriers were unrelated to allelic variation in the BDNF Val66Met polymorphism (Fig 1C,D ; Table 6 ). This dissociation between rate of increase in CSF tau and rate of cortical Aβ accumulation, and the development of clinical symptoms in DIAD, raises the hypothesis that in preclinical mutation carriers, increased rate of cognitive decline and hippocampal volume loss observed in Met66 carriers is a consequence of biological processes associated with increasing CSF tau and ptau 181 , most likely reflecting neuronal injury and presence of neurofibrillary tangles.
Finally, we confirmed that Aβ positivity is necessary for the cognitive decline, neurodegeneration, and tau accumulation associated with Met66 carriers. In agematched mutation noncarriers who showed no evidence of amyloidosis, rates of cognitive decline, hippocampal volume loss, increases in CSF tau and ptau 181 , and cortical Aβ accumulation did not change with increasing age for either Met66 carriers or Val66 homozygotes (Fig 2) . This is consistent with observations by us [6] [7] [8] and others 9 that BDNF Val66Met has no effect on cognitive decline or hippocampal volume loss in Aβ-negative adults. The necessity of Aβ positivity for cognitive decline in Met66 carriers led us to propose that equivocal findings on the effect of BDNF Val66Met on cognitive decline observed in previous studies 20 are likely attributed to their not accounting for the presence of Aβ positivity in their samples. Recently, in a large group of middle-aged adults, Met66 carriers showed faster cognitive decline than Val66 homozygotes. 9 However, when Aβ levels were considered, only Aβ-positive Met66 carriers showed increased cognitive decline when compared to matched Aβ-negative controls. 9 Thus, our current results, and that of previous studies, [6] [7] [8] [9] [10] indicate that whereas Met66 is unrelated to accumulation of Aβ itself, Aβ positivity is necessary for cognitive decline and hippocampal volume loss in Met66 carriers.
The finding that, in preclinical DIAD mutation carriers, the presence of at least one copy of the BDNF Met66 allele increased the rate of cognitive decline, hippocampal volume loss, as well as the rate of increase in CSF tau and ptau 181 indicates that Met66 acts to accelerate symptom onset early in DIAD. This is consistent with, and extends, our previous cross-sectional findings that the Met66 allele is important for timing of cognitive decline in DIAD. 10 It also accords with studies of preclinical sporadic AD in different samples, where the Met66 allele is associated with increased cognitive decline and brain volume loss. [6] [7] [8] [9] The effect of the Met66 allele on the clinical expression of DIAD is important given that the rate of cognitive decline in Met66 carriers was 4 times faster and the rate of hippocampal volume loss was 16 times faster than in Val66 homozygotes. Additionally, Met66 carriers showed increases in levels of CSF tau and ptau 181 that were 6 times greater than those observed in Val66 homozygotes. The effects of the BDNF Met66 allele on AD clinical markers and biomarkers in this study also illustrate an important dissociation between the effects of tau and Aβ on the clinical manifestation of AD pathophysiology. Although it is generally agreed that both Aβ and tau accumulation are necessary for development of AD dementia, 21 the processes by which these aggregating proteins interact to influence clinical disease progression remain unclear. 22 It is well established that a DIAD mutation results in a rapid increase in Aβ accumulation, neurodegeneration, and cognitive decline. 1, 5 However, the finding that the Met66 allele is associated with faster cognitive decline and hippocampal volume loss, and with increases in CSF tau, but is not associated with cortical Aβ accumulation, suggests strongly that the deleterious effects of tau on neurons occurs downstream of Aβ positivity. Furthermore, our data suggest that the effect of Aβ positivity on neurodegeneration and cognitive decline is crucially linked to increasing CSF tau and ptau 181 .
Although the current findings are consistent with the proposed temporal sequence of AD biomarker changes and their clinical manifestation, 23 it remains unclear how
Met66 intersects these models to increase the rate of change in CSF tau and ptau 181 . For example, Met66 may be associated with lower levels of CNS BDNF, which may facilitate increases in tau, which, in turn, accelerate neurodegeneration. However, it is also possible that lower levels of CNS BDNF allow faster Aβ-positive-related neurodegeneration, of which increased tau is a consequence. It is suggested commonly that the clinical manifestation of AD is related more strongly to tau rather than to Aβ. 24 The current data suggest this statement is too simple. All estimates have been adjusted for APOE ε4, depressive levels, and race. CSF = cerebrospinal fluid; NC = nonmutation carrier; PACC = preclinical Alzheimer cognitive composite; SE = standard error; PiB-PET SUVR = positron emission tomography (using Pittsburgh compound B) standardized uptake value ratio.
Rather, whereas early clinical presentation of AD is related strongly to increasing CSF tau and ptau 181 , this is only in the presence of Aβ positivity. Current in vitro models show that expression of human tau and BDNF levels is inversely related, even preceding the formation of neurofibrillary tangles. However, these models propose that it is tau that downregulates BDNF expression. 25 If the faster cognitive decline and neurodegeneration in Met66 carriers observed here were a consequence of greater downregulation of BDNF by tau, then increases in CSF tau should be equivalent in preclinical mutation carriers who are Met66 carriers and Val66 homozygotes. The specific association between Met66 and increasing CSF tau observed here suggests that increases in CSF tau were a consequence, rather than a cause, of reduced CNS BDNF in humans. This suggestion is supported by our observation that in the absence of Aβ positivity (ie, in nonmutation carriers), carriage of the Met66 allele did not influence tau levels (Fig 2) . It is also consistent with findings that reduced BDNF in cells slows the dephosphorylation of tau through slowing TrkB activation, 26 and that in AD postmortem samples, BDNF loss is specific to tangle-bearing neurons. 27 Given that the Met66 allele is associated with lower expression of CNS BDNF, the large effect of the BDNF Met66 allele on CSF tau, cognitive decline, and neurodegeneration in the preclinical DIAD mutation carriers also accords with the importance of CNS BDNF in synaptic excitation, longterm potentiation, and neuronal plasticity. 28, 29 It is also consistent with studies using AD rodent models that show that BDNF mRNA is reduced substantially in the hippocampus and temporal lobe, [28] [29] [30] with the extent of BDNF loss associated with the magnitude of cognitive impairment. 28, 30, 31 Furthermore, postmortem analysis of BDNF RNA in AD patients suggest that low CNS BDNF expression is associated with increased cognitive decline before death. 31 Another pathway through which BDNF may potentially operate to influence rates of neurodegeneration and cognitive decline is by responding to inflammatory processes early in the AD course. 13, 32 For example, BDNF production by astrocytes increases to counteract the deleterious effects of Aβ, 32 and this is posited to represent an attempt to rescue or buffer neurons against AD pathogenesis. 13 Additionally, administration of pioglitazone significantly restored BDNF levels and attenuated inflammatory markers in mice treated with intracerebroventricular Aβ. 33 Thus, it is possible that lower levels of CNS BDNF in Met66 carriers may increase susceptibility to Aβ and tau toxicity by moderating inflammation. Future studies could test this hypothesis in humans by determining whether inflammatory markers are related to allelic variation in BDNF Val66Met in a manner similar to that observed for CSF tau, brain volume loss, and cognitive decline. Generalizations of the results from this study should take into account the relatively small sample size and the short follow-up period (3.5 years). It will be important for these findings to be replicated in future studies of DIAD mutation carriers over longer periods of follow-up. Given the complete penetrance of DIAD, we expect that if followed over longer periods, MC Val66 homozygotes will start to show cognitive decline arising from neurodegeneration and this will also be associated with increasing levels of CSF tau and ptau 181 , albeit at an older age. Nonetheless, this study demonstrates that the deleterious effects of Aβ in DIAD were increased in preclinical mutation carriers who carried the BDNF Met66 allele. Another avenue of future investigation will be the relationship between peripheral markers of BDNF and increases in tau, brain volume loss, and cognitive decline. Although some studies observe CSF and plasma levels of BDNF to be reduced in sporadic AD, this finding is not consistent and the extent to which such changes relate to clinical disease markers has not been established. 34, 35 Taken together, the results of this study provide more evidence that common biological factors influence the development of dementia in DIAD and sporadic AD. The strength and consistency of our results with those in sporadic AD also suggest that increasing CNS BDNF levels may be a viable therapeutic strategy for reducing the effects of amyloidosis on disease progression. Our results also suggest strongly that the BDNF Val66Met polymorphism should be considered as a potential moderator of clinical trial outcomes in current treatment and prevention trials in DIAD and sporadic AD.
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